Omeros (OMER) Receivables (2010 - 2026)
Omeros (OMER) posted Receivables of $12.1 million for Q1 2026, up 3.92% sequentially from $11.7 million in Q4 2025, and up 42.23% YoY from $8.5 million in Q1 2025.
Omeros (OMER) Receivables (2010 - 2026) Analysis & Trends
Omeros has reported Receivables for 17 years, with the latest figure at $12.1 million in Q1 2026.
- Quarterly Receivables rose 42.23% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (up 42.23% YoY) and the FY2025 annual result came in at $11.7 million, up 36.65% from the prior year.
- Receivables climbed to $12.1 million in Q1 2026 per OMER's latest filing, from $11.7 million in the prior quarter.
- Over five years, Receivables peaked at $213.5 million in Q4 2022 and troughed at $6.7 million in Q3 2024.
- A 5-year average of $22.3 million and a median of $9.5 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables soared 436.3% in 2022, then plunged 95.56% in 2023.
- Over 5 years, Receivables stood at $213.5 million in 2022, then slumped by 95.56% to $9.5 million in 2023, then dropped by 9.82% to $8.5 million in 2024, then surged by 36.65% to $11.7 million in 2025, then increased by 3.92% to $12.1 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $12.1 million, $11.7 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 21.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.41 Mn |
| Mar 31, 2026 | 12.12 Mn |
| Dec 31, 2025 | 11.67 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Jun 30, 2025 | 7.34 Mn |
| Mar 31, 2025 | 8.52 Mn |
| Dec 31, 2024 | 8.54 Mn |
| Sep 30, 2024 | 6.69 Mn |
| Jun 30, 2024 | 9.35 Mn |
| Mar 31, 2024 | 8.30 Mn |
| Dec 31, 2023 | 9.47 Mn |
| Sep 30, 2023 | 7.10 Mn |
| Jun 30, 2023 | 11.32 Mn |
| Mar 31, 2023 | 10.34 Mn |
| Dec 31, 2022 | 213.48 Mn |
| Sep 30, 2022 | 14.60 Mn |
| Jun 30, 2022 | 15.29 Mn |
| Mar 31, 2022 | 16.71 Mn |
| Dec 31, 2021 | 39.81 Mn |
| Sep 30, 2021 | 33.90 Mn |